Ocular Therapeutix™ Announces First Subjects Screened in Phase 3 Pivotal Clinical Trial of AXPAXLI™ in Wet AMD

February 13, 2024

https://www.globenewswire.com/news-release/2024/02/13/2828143/0/en/Ocular-Therapeutix-Announces-First-Subjects-Screened-in-Phase-3-Pivotal-Clinical-Trial-of-AXPAXLI-in-Wet-AMD.html

BEDFORD, Mass., Feb. 13, 2024 (GLOBE NEWSWIRE) — Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that the first three subjects have been screened and received their first aflibercept injection in the Phase 3 SOL-1 clinical trial of AXPAXLI™ (axitinib intravitreal implant, also known as OTX-TKI) for the treatment of wet age-related macular degeneration (wet AMD). The Company previously announced FDA agreement on its Special Protocol Assessment (SPA) Agreement Modification on January 25th.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.